Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 4/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | AOC1 | P19801 | 5/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18924363 | 0.88 | TDP1 (0.43) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL13261338 | 0.84 | TDP1 (0.49) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL17772009 | 0.83 | CYP2E1 (0.45) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL10954433 | 0.82 | CYP2E1 (0.51) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL214076 | 0.82 | — | — | |
| SCHEMBL14945019 | 0.81 | TAAR1 (0.52) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL6628774 | 0.81 | TKT (0.39) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| SCHEMBL21983945 | 0.79 | TAAR1 (0.50) | TRPA1 | |
| SCHEMBL8271491 | 0.78 | CYP2E1 (0.49) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 | |
| Iodomethane SCHEMBL11651462 | 0.78 | CYP2E1 (0.43) | CYP2E1CYP2C8CYP2D6CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796800-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-10-24 | — | — | US | claimed |
| US-20160108153-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| CN-103154044-B | Process for producing polydienes | BRIDGESTONE CO.,LTD. (JP) | 2016-02-17 | — | — | CN | claimed |
| US-9249244-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2016-02-02 | — | — | US | claimed |
| EP-2619233-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2013-07-31 | — | — | EP | claimed |
| WO-2012040026-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | WO | claimed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2012092547-A1 | BULK POLYMERIZATION OF CONJUGATED DIENES USING A NICKEL-BASED CATALYST SYSTEM | BRIDGESTONE CORPORATION (JP) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012092551-A1 | BULK POLYMERIZATION OF CONJUGATED DIENES USING A NICKEL-BASED CATALYST SYSTEM | BRIDGESTONE CORPORATION (JP) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012040026-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | WO | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| US-20100076011-A1 | Enantiomer-Pure Hexahydro-Pyrrolocyclopenta-Pyridine Derivatives | BINDER, EVA (AT) | 2010-03-25 | — | — | US | disclosed |
| US-4161598-A | ANALGESICS, NARCOTIC ANTAGONISTS | STERLING DRUG INC. (US) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076011-A1 | Enantiomer-Pure Hexahydro-Pyrrolocyclopenta-Pyridine Derivatives | FFAR3, FFAR2, FFAR1 | CYP2E1 91/4885CYP2C8 320/4885CYP2D6 98/4885 |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | CYP2E1 309/4885CYP2C8 423/4885CYP2D6 363/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | CYP2E1 309/4885CYP2C8 423/4885CYP2D6 363/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CYP2E1 1219/4885CYP2C8 1607/4885CYP2D6 571/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | CYP2E1 863/4885CYP2C8 950/4885CYP2D6 760/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CYP2E1 1219/4885CYP2C8 1607/4885CYP2D6 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.